Company / Cash & Equivalents
Tyra Biosciences, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$92.0M
FY2024
5-year range
$15.2M / $302.2M
FY2020-FY2024
Trend
+58.5%
vs FY2023
Sector context
#145 of 207
Health Care
What the data says
At $92M, Tyra Biosciences, Inc.'s cash & equivalents ranks #145 of 207 in the Health Care sector. Cash & Equivalents returned to growth in FY2024 after 2 years of decline, reaching $92M.
Based on SEC 10-K filings.
$92M in FY2024 with a 3-year CAGR of -32.7%.
Declined from $251M to $92M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -32.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#145 of 207 in Health CareTop 70% of 207This company $92.0M Sector average $669.5M
▼
-86.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -32.7%, indicating a declining trend.
- In FY2024, cash & equivalents increased 58.5% year-over-year.
- Ranks #145 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $92.0M | +58.5% |
| FY2023 | $58.0M | -76.9% |
| FY2022 | $251.2M | -16.9% |
| FY2021 | $302.2M | +1884.9% |
| FY2020 | $15.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026